WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% – Time to Sell?

WAVE Life Sciences Ltd. (NASDAQ:WVE)’s share price was down 4.3% during mid-day trading on Wednesday . The stock traded as low as $4.82 and last traded at $4.7550. Approximately 356,537 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 3,805,564 shares. The stock had previously closed at $4.97.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on WVE. Mizuho cut their price target on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. UBS Group set a $13.00 price objective on shares of WAVE Life Sciences in a research note on Monday, August 3rd. Zacks Research lowered WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Wedbush cut their target price on WAVE Life Sciences from $15.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Finally, B. Riley Financial reduced their price target on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.53.

WAVE Life Sciences Price Performance

The firm has a fifty day moving average of $5.70 and a two-hundred day moving average of $7.68. The stock has a market capitalization of $936.96 million, a P/E ratio of -4.37 and a beta of -1.26.

WAVE Life Sciences (NASDAQ:WVE) last posted its earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. The business had revenue of $2.27 million for the quarter, compared to analysts’ expectations of $7.45 million. As a group, sell-side analysts forecast that WAVE Life Sciences Ltd. will post -1.11 EPS for the current fiscal year.

Insider Activity at WAVE Life Sciences

In related news, Director Heidi L. Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company’s stock, valued at $270,029.30. This trade represents a 13.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Adrian Rawcliffe sold 12,700 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 23,564 shares of company stock worth $132,476. 24.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of large investors have recently added to or reduced their stakes in the company. GSK plc bought a new position in shares of WAVE Life Sciences during the 4th quarter worth approximately $310,177,000. Darwin Global Management Ltd. acquired a new stake in WAVE Life Sciences in the fourth quarter valued at approximately $125,168,000. Readystate Asset Management LP purchased a new position in WAVE Life Sciences in the second quarter worth $27,465,000. Price T Rowe Associates Inc. MD grew its holdings in WAVE Life Sciences by 83.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock worth $125,927,000 after purchasing an additional 3,362,880 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock worth $97,607,000 after purchasing an additional 2,500,000 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.